Skip to main content
SpringerLink
Log in

Neue Aspekte zur Therapie mit Klasse-III-Antiarrhythmika

  • Conference paper
Book cover Medikamentöse Behandlung des Postinfarktpatienten nach CAST

  • 19 Accesses

Zusammenfassung

Die Verlängerung der Aktionspotentialdauer als antiarrhythmisches Wirkprinzip wurde erstmals von Vaughan Williams beschrieben. Die ersten Beobachtungen, die diesen Schluß nahelegten, resultierten aus Experimenten an kardialen Geweben hypothyreoter Tiere, in denen eine uniforme Verlängerung des Aktionspotentials nachweisbar war (13, 22). Die Tatsache, daß bei hypothyreoten Patienten kaum Arrhythmien beobachtet werden, wurde durch diese Zunahme der effektiven Refraktärperiode erklärt. In den siebziger Jahren wurden dann einzelne antiarrhythmisch wirkende Substanzen isoliert und untersucht, die vorwiegend durch die Hemmung der Repolarisationsvorgänge Rhythmusstörungen supprimieren. Die Hauptvertreter dieser nach Vaughan Williams als Klasse III bezeichneten Antiarrhythmika sind Amiodaron (29) und Sotalol (43).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Anderson JL (1984) Antifibrillatory versus therapy. Am J. Cardiol 54: 7–13

    Article  Google Scholar 

  2. Borggrefe M, Podzeck A, Breithard G (1986) Sotalol in vertricular tachyarrhythmia: electro-physiologic effects and long-term results. Circulation 74 (Suppl II) 1243

    Article  Google Scholar 

  3. Burckhardt D, Pfisterer M, Hoffmann A et al (1983) Effects of the beta-adrenoceptor blocking agent Sotalol on ventricular arrhythmias in patients with chronic ischemic heart disease. Cardiology 70 (Suppl 1): 114–21

    Article  PubMed  Google Scholar 

  4. Burkart F, Pfisterer M, Kiowski W, Burckhardt D, Follath F (1989) Improved survival of patients with asymptomatic ventricular arrhythmias after myocardial infarction with amiodarone: a randomized, controlled trial. Circulation 80 (Suppl II): 476

    Google Scholar 

  5. Cairns JA, Connolly SJ, Gent M, Roberts RS (1990) Canadian Amiodarone Myocardial Infarction Arrhythmia Trial (CAMIAT) Pilot results. Circulation 82 (Suppl III): 548

    Google Scholar 

  6. Campbell JJ, Gavaghan TP, Morgan JJ (1985) Intravenous sotalol for the treatment of atrial fibrillation and flutter after cardiopulmonary bypass. Comparison with disopyramide and dioxin in a randomized trial. Br Heart J 54: 86–90

    Article  PubMed  CAS  Google Scholar 

  7. Carmeliet E (1985) Electrophysiologic and voltage clamp analysis of effects of sotalol on isolated cardiac muscle and Purkinje fibers. J Pharmacol Exp Ther 232: 817–25

    PubMed  CAS  Google Scholar 

  8. Charlier R, Deltour G, Baudine A, Chaillet F (1968) Pharmacology of amiodarone, an antianginal drug with a new biological profile. Arzneimittelforschung 18: 1408–1411

    PubMed  CAS  Google Scholar 

  9. Cobb LA, Baum RS, Alvarez H, Schaffer WA (1975) Resuscitation from out-of-hospital ventricular fibrillation: 4 years follow-up. Circulation 51–52 (Suppl III): 223–228

    Google Scholar 

  10. Cohen-Armon M, Schreiber G, Sokolovsky M (1984) Interaction of the antiarrhythmic drug amiodarone with the muscarinic receptor in rat heart and brain. J Cardiovasc Pharmacol 6: 1148–1153

    PubMed  CAS  Google Scholar 

  11. Cook NS (1988) The pharmacology of potassium channels and their therapeutic potential. TIPS 9: 21–28

    PubMed  CAS  Google Scholar 

  12. DiCarlo LA, Morady F, Sauve MJ et al (1985) Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables. Am J Cardiol 55: 372–374

    Article  PubMed  Google Scholar 

  13. Freedberg AS, Papp JG, Vaughan Williams EM (1970) The effect of altered thyroid state on atrial intracellular potentials. J Physiol 207: 357–370

    PubMed  CAS  Google Scholar 

  14. Fogelman F, Lightman SL, Sillet RM, et al (1972) The treatment of cardiac arrhythmias with sotalol. Eur J Clin Pharmacol 15: 72

    Article  Google Scholar 

  15. Gonzales R, Scheinman MM, Herre JM, et al (1988) Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. J Am Coll Cardiol 12: 1568–72

    Article  Google Scholar 

  16. Heger JJ, Prystowski EN, Zipes DP (1983) Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation. Am Heart J 106: 887–894

    Article  PubMed  CAS  Google Scholar 

  17. Herre JM, Sauve MJ, Malone P, et al (1989) Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 13: 442–449

    Article  PubMed  CAS  Google Scholar 

  18. Hohnloser SH (1990) Sotalol — Hämodynamisches Wirkprofil. Herzschr Elektrophys 1: 82 - 85

    Google Scholar 

  19. Holland K, Patterson E, Lucchesi BR (1983) Prevention of ventricular fibrillation by bretylium in a conscious canine model of sudden coronary death. Am Heart J 195: 159–174

    Google Scholar 

  20. Holt DW, Tucker GT, Jackson PR, McKenna WJ (1986) Amiodarone pharmacokinetics. Br J Clin Pract 40 (Suppl 44): 109–115

    Google Scholar 

  21. Hondeghem LM, Synders DJ (1990) Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 81: 686–690

    Google Scholar 

  22. Johnson PN, Freedberg AS, Marshall JM (1973) Action of thyroid hormone on the transmembrane potentials from sinoatrial node cells and atrial cells in isolated atria of rabbits. Cardiology 82: 273–289

    Article  Google Scholar 

  23. Kato R, Yabek S, Ikeda N et al (1986) Electrophysiologic effects of dextro- and levo-isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics. J Am Coll Cardiol 7: 116–25

    Article  PubMed  CAS  Google Scholar 

  24. Lidell C, Rehniquist N, Sojgren A et al (1985) Comparative efficacy of oral sotalol and procainamide in patients with chronic ventricular arrhythmias: a multicenter study. Am Heart J 109: 970–75

    Article  PubMed  CAS  Google Scholar 

  25. Lynch JJ, Coskey LA, Montgomery DG, Benedict BR (1985) Prevention of ventricular fibrillation by dextrorotatory sotalol in a conscious canine model of sudden coronary death. Am Heart J 109: 949–958

    Article  PubMed  CAS  Google Scholar 

  26. Manz M, Kuhl AJ, Lüderitz B (1985) Sotalol bei supraventrikulärer Tachykardie: Elektrophysiologische Messungen beim Wolff-Parkinson-White Syndrom und AV-Knoten Reentrytachykardie. Z Kardiol 74: 500–05

    Google Scholar 

  27. Mason JW, Hondeghem LM, Katzung BG (1983) Amiodarone blocks inactivated cardiac sodium channels. Pflügers Arch 396: 79–81

    Article  PubMed  CAS  Google Scholar 

  28. Mason JW, Hondeghem LM, Katzung BG (1984) Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res 55: 277–285

    CAS  Google Scholar 

  29. Mason JW (1987) Amiodarone: N Engl J Med 316: 455–466

    Article  PubMed  CAS  Google Scholar 

  30. Mitchell L, Wyse DG, Duff HJ (1987) Electropharmacology of Sotalol in patients with Wolff-Parkinson-White syndrome. Circulation 76: 810–18

    Article  PubMed  CAS  Google Scholar 

  31. Morady F, Sauve MJ, Malone P, et al (1983) Long-term efficacy and toxicity of high dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 52: 975–979

    Article  PubMed  CAS  Google Scholar 

  32. Myers M, Peter T, Weiss D, Nalos PC, Gang ES, Oseran DS, Mandel WJ (1990) Benefit and risks of long-term amiodarone therapy for sustained ventricular tachycardia/fibrillation: minimum of three-year follow-up in 145 patients. Am Heart J 119: 8–14

    Article  PubMed  CAS  Google Scholar 

  33. Nademanee K, Singh BN, Hendrickson J, et al (1983) Amiodarone in life-threatening ventricular arrhythmias. Ann Int Med 98: 577–584

    PubMed  CAS  Google Scholar 

  34. Nademanee K, Feld G, Hendrickson JA, et al (1985) Electrophysiologic and antiarrhythmic effects of Sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 72: 555–564

    Article  PubMed  CAS  Google Scholar 

  35. Nademanee K, Singh BN (1990) Effects of Sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation. Comparison with other antiarrhythmic agents. Am J Cardiol 65: 53A–57A

    Article  PubMed  CAS  Google Scholar 

  36. Patterson E, Lucchesi BR (1984) Antifibrillatory properties of beta adrenergic receptor antagonists, nadolol, Sotalol, atenolol, and propranolol in the anesthetized dog and rabbit cardiac tissue. Pharmacology 28: 121–129

    Google Scholar 

  37. Pennefather P, Cohen IS (1990) Molecular mechanisms of cardiac K+-channel regulation. In: Zipes DP, Jalife J (eds) Cardiac electrophysiology. WB Saunders Company, Philadelphia, pp 882–897

    Google Scholar 

  38. Prakash R, Parmley WW, Allen HN, Matloff JM (1972) Effect of Sotalol on clinical arrhythmias. Am J Cardiol 29: 397

    Article  PubMed  CAS  Google Scholar 

  39. Rizos I, Senges J, Jauernig R, et al (1984) Differential effects of Sotalol and metoprolol on induction of paroxysmal supraventricular tachycardia. Am J Cardiol 53: 1022–29

    Article  PubMed  CAS  Google Scholar 

  40. Senges J, Lengfelder W, Jauernig R, et al (1984) Electrophysiologic testing of therapy with Sotalol for sustained ventricular tachycardia. Circulation 69: 577–583

    Article  PubMed  CAS  Google Scholar 

  41. Singh B, Vaughan Williams EM (1979) A third class of antiarrhythmic action: effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle of MJ 1999 and AH 3676. Br J Pharmacol 39: 675–89

    Google Scholar 

  42. Singh BN, Nademanee K (1985) Control of cardiac arrhythmias by lenghtening of repolarization: theoretic considerations and clinical observations. Am Heart J 109: 421–430

    Article  PubMed  CAS  Google Scholar 

  43. Singh BN, Nademanee K (1987) Sotalol: a beta blocker with unique antiarrhythmic properties. Am Heart J: 114: 121–139

    Article  PubMed  CAS  Google Scholar 

  44. Singh BN, Courtney KR (1990) The classification of antiarrhythmic mechanisms of drug action: Experimental and clinical considerations. In: Zipes DP, Jalife J (eds) Cardiac electrophysiology. WB Saunders Company, Philadelphia, pp 882–897

    Google Scholar 

  45. Steinbeck G, Bach P, Haberl R (1986) Electrophysiologic and antiarrhythmic efficacy of oral Sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatory electrocardiogram. J Am Coll Cardiol 8: 949–958

    Article  PubMed  CAS  Google Scholar 

  46. The Cardiac Arrhythmia Suppression Trial (CAST) investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406–412

    Article  Google Scholar 

  47. Vrobel TR, Miller PE, Mostow ND, Rakita L (1989) A general overview of amiodarone toxicity: its prevention, detection, and management. Progr Cardiovasc Dis 31: 393–426

    Article  CAS  Google Scholar 

  48. Weirich J, Antoni H (1990) Differential analysis of the frequency-dependent effects of class 1 antiarrhythmic drugs according to periodical ligand binding: implications for antiarrhythmic and proarrhythmic efficacy. J Cardiovasc Pharmacol 15: 998–1009

    Article  PubMed  CAS  Google Scholar 

  49. Woosley RL (1990) Antiarrhythmic agents: pharmacokinetics and pharmacodynamics. In: Zipes DP, Jalife J (eds) Cardiac electrophysiology. WB Saunders Company, Philadelphia, pp 872–882

    Google Scholar 

  50. Woosley RL, Barbey JT, Wang T, Funck-Bretano C (1990) Concentration/response relations for the multiple-antiarrhythmic actions of Sotalol. Am J Cardiol 65: 22A–27A

    Article  PubMed  CAS  Google Scholar 

  51. Yabek SM, Kato R, Singh BN (1985) Acute effects of amiodarone on the electrophysiologic properties of isolated neonatal and adult cardiac fibres. J Am Coll Cardiol 5: 1109–1115

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Universitätsklinik III, Hugstetterstr. 55, 7800, Freiburg, Germany

    Priv.-Doz. Dr. S. Hohnloser, M. Zabel, M. Zehender & H. Just

Authors
  1. Priv.-Doz. Dr. S. Hohnloser
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Zabel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Zehender
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Just
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. I. Medizinische Klinik, Technischen Universität München Klinikum rechts der Isar, Ismaninger Straße 22, 8000, München 80, Germany

    Georg Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 1991 Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt

About this paper

Cite this paper

Hohnloser, S., Zabel, M., Zehender, M., Just, H. (1991). Neue Aspekte zur Therapie mit Klasse-III-Antiarrhythmika. In: Schmidt, G. (eds) Medikamentöse Behandlung des Postinfarktpatienten nach CAST. Steinkopff. https://doi.org/10.1007/978-3-642-85414-9_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85414-9_6

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-642-85415-6

  • Online ISBN: 978-3-642-85414-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation